FORM 6-K
 
 
 
SECURITIES AND EXCHANGE COMMISSION

 
Washington D.C. 20549
 
Report of Foreign Issuer
 
 
 
Pursuant to Rule 13a-16 or 15d-16 of

 
the Securities Exchange Act of 1934
 
 
 
For period ending 19 June 2017 
 
GlaxoSmithKline plc
 
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
 
(Address of principal executive offices)

 
Indicate by check mark whether the registrant files or
 
will file annual reports under cover Form 20-F or Form 40-F

 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
 
information contained in this Form is also thereby furnishing the
 
information to the Commission pursuant to Rule 12g3-2(b) under the
 
Securities Exchange Act of 1934.

 
 
 
Issued: Monday 19 June 2017, London UK - LSE
 
 
GSK confirms start date for Luke Miels
 
 
 
GSK has reached an agreement with AstraZeneca that Luke Miels will commence his appointment as President, Global Pharmaceuticals, GSK  on 4 September 2017. 
 
 
 
GSK enquiries:
 
 
 
UK Media enquiries:
Simon Steel
+44 (0) 20 8047 5502
(London)
 
David Mawdsley
+44 (0) 20 8047 5502
(London)
 
 
 
 
 
 
 
 
US Media enquiries:
Sarah Alspach
+1 202 715 1048
(Washington, DC)
 
Sarah Spencer
+1 215 751 3335
(Philadelphia)
 
 
 
 
 
 
 
 
Analyst/Investor enquiries:
Sarah Elton-Farr
+44 (0) 20 8047 5194
(London)
 
Tom Curry
+ 1 215 751 5419
(Philadelphia)
 
Gary Davies
+44 (0) 20 8047 5503
(London)
 
James Dodwell
+44 (0) 20 8047 2406
(London)
 
Jeff McLaughlin
+1 215 751 7002
(Philadelphia)
 
 GSK cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016.   
 
 
 
 
Registered in England & Wales:
 
No. 3888792
 
 
 
 
Registered Office:
 
980 Great West Road
 
Brentford, Middlesex
 
TW8 9GS
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
GlaxoSmithKline plc
 
 
(Registrant)
 
 
 
Date: June 19, 2017 
 
 
 
 
 
By: VICTORIA WHYTE--------------------------
 
 
 
 
Victoria Whyte
 
 
Authorised Signatory for and on
 
 
behalf of GlaxoSmithKline plc